Echinocandin antifungals: review and update (Q36441524)

14 August 2017

1 reference

title

Echinocandin antifungals: review and update (English)

1 reference

14 August 2017

Vicki A Morrison

1

1 reference

14 August 2017

1 April 2006

1 reference

Expert Review of Anti-infective Therapy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

2

1 reference

14 August 2017

325-342

1 reference

Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

First reported use of caspofungin in an extremely low-birth-weight neonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Management of endogenous fungal endophthalmitis with voriconazole and caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin for Candida endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Anidulafungin: review of a new echinocandin antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro activity of anidulafungin against selected clinically important mold isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Caspofungin in a pediatric patient with persistent candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.325

Byssochlamysol, a New Antitumor Steroid against IGF-1-dependent Cells from Byssochlamys nivea. I. Taxonomy, Fermentation, Isolation and Biological Activity.

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.56.1

WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.

12 April 2024

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.1084

Identifiers

DOI

10.1586/14787210.4.2.325

1 reference

14 August 2017

1 reference

PubMed ID

16597212